Recap of key themes from the ISPOR 2019 conference including ICER's increasing influence in the US, non-traditional funding mechanisms for high-cost therapies, future trends impacting value story communication, and focus on MedTech.

DRG's Insights to Access

Insights from ISPOR 2019

Expert analysts from DRG's global market access, clinical outcomes assessment, and digital teams share previews of research to be presented at the ISPOR 2019 conference.

Patient, Prescriber, and Payer Insights for ISPOR

Expert discussion on current news and trends in Rare Disease for Europe and the US

Current News and Trends in Rare Disease

Continuing the discussion on agency collaboration, we expand the scope to look at HTA and marketing authorization collaborations in Europe and other countries outside of the US.

Part 2: Agency Collaboration in Health Technology Assessment

The US-based, independently operated Institute for Clinical and Economic Review (ICER) has established a partnership with the UK’s National Institute for Health Care and Excellence (NICE) and the Canadian Agency for Drugs and Technologies in Health (CADTH), on how to measure value for high-cost gene therapies. What does this mean for the industry? 

Part 1: Agency Collaboration in Health Technology Assessment

Expert analysis of the latest news and trends impacting global market access for drug therapies and medical devices.

hubhopper

DRG's Insights to Access

hubhopper